An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 26 Jul 2018 Planned number of patients changed from 67 to 73.
- 28 Aug 2017 Status changed from not yet recruiting to recruiting.
- 07 Jul 2017 New trial record